User profiles for "author:Amit Bar-Or"
Amit Bar-OrProfessor, University of Pennsylvania Verified email at pennmedicine.upenn.edu Cited by 48905 |
Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions
The onset of multiple sclerosis (MS) in childhood poses diagnostic and therapeutic
challenges, particularly if the symptoms of the first demyelinating event resemble acute …
challenges, particularly if the symptoms of the first demyelinating event resemble acute …
Roles of microglia in brain development, tissue maintenance and repair
The emerging roles of microglia are currently being investigated in the healthy and diseased
brain with a growing interest in their diverse functions. In recent years, it has been …
brain with a growing interest in their diverse functions. In recent years, it has been …
[HTML][HTML] Teriflunomide and its mechanism of action in multiple sclerosis
A Bar-Or, A Pachner, F Menguy-Vacheron, J Kaplan… - Drugs, 2014 - Springer
Abstract Treatment of multiple sclerosis (MS) is challenging: disease-modifying treatments
(DMTs) must both limit unwanted immune responses associated with disease initiation and …
(DMTs) must both limit unwanted immune responses associated with disease initiation and …
[HTML][HTML] B-cell depletion with rituximab in relapsing–remitting multiple sclerosis
Background There is increasing evidence that B lymphocytes are involved in the
pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a …
pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a …
[HTML][HTML] Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis
Background BG-12 (dimethyl fumarate) was shown to have antiinflammatory and
cytoprotective properties in preclinical experiments and to result in significant reductions in …
cytoprotective properties in preclinical experiments and to result in significant reductions in …
[HTML][HTML] Ocrelizumab versus placebo in primary progressive multiple sclerosis
Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …
[HTML][HTML] Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …
[HTML][HTML] Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
SARS-CoV-2 messenger RNA vaccination in healthy individuals generates immune
protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine …
protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine …
IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases
P Shen, T Roch, V Lampropoulou, RA O'Connor… - Nature, 2014 - nature.com
B lymphocytes have critical roles as positive and negative regulators of immunity. Their
inhibitory function has been associated primarily with interleukin 10 (IL-10) because B-cell …
inhibitory function has been associated primarily with interleukin 10 (IL-10) because B-cell …
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Background No treatment has consistently shown efficacy in slowing disability progression
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …